NCT06955234

Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose

Berbevis Project: Multitarget Dose-finding Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Azienda di Servizi alla Persona di Pavia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg/dL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.

Conditions

• Impaired Fasting Glucose (IFG)

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Berbevis supplement	This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.

Timeline

• Start date: 2026-06-15
• Primary completion: 2026-07-15
• Completion: 2026-09-15
• First posted: 2025-05-02
• Last updated: 2025-11-25